crizotinib and Long-QT-Syndrome

crizotinib has been researched along with Long-QT-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for crizotinib and Long-QT-Syndrome

Article	Year
Crizotinib-induced simultaneous multiple cardiac toxicities. Investigational new drugs, 2018, Volume: 36, Issue:5 Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed. Topics: Adenocarcinoma; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiotoxicity; Crizotinib; Female; Humans; Long QT Syndrome; Lung Neoplasms; Middle Aged; Pericarditis; Protein Kinase Inhibitors; Proto-Oncogene Mas	2018
Pneumologie (Stuttgart, Germany), 2016, Volume: 70, Issue:12 Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Bradycardia; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Long QT Syndrome; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Treatment Failure	2016

Article

Year

Crizotinib-induced simultaneous multiple cardiac toxicities.

Investigational new drugs, 2018, Volume: 36, Issue:5

Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricular fibrillation, and pericarditis simultaneously. The cardiotoxicity of crizotinib can sometimes be simultaneous; thus, intensive observation is needed.

Topics: Adenocarcinoma; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiotoxicity; Crizotinib; Female; Humans; Long QT Syndrome; Lung Neoplasms; Middle Aged; Pericarditis; Protein Kinase Inhibitors; Proto-Oncogene Mas

2018

Pneumologie (Stuttgart, Germany), 2016, Volume: 70, Issue:12

Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Bradycardia; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Long QT Syndrome; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Treatment Failure

2016